Neurovascular Devices | Market Insights | Europe | 2021

Although the COVID-19 pandemic will have a modest impact on the market in the short term, the European market for neurovascular devices will grow moderately once the impact subsides, driven by the adoption of innovative devices backed by favorable clinical data and rising demand for neurovascular procedures among Europe’s large aging population.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for neurovascular devices in Europe across a 10-year period.

The COVID-19 pandemic will impact the market in the short term.

How strongly will the market be affected?

Which procedures will experience the strongest impact?

How quickly will recovery occur?

The positive results of the DAWN trial have extended the treatment window for AIS events.

How will the extended treatment window of a stroke event impact neurovascular thrombectomy procedure volumes?

How do the AIS treatment landscapes differ between European countries?

Many competitors are entering the neurovascular thrombectomy device market in Europe.

How will new products impact the neurovascular thrombectomy device market?

What challenges will new companies encounter in this space? Will they capture significant share from existing competitors?

The flow-diverting device market is seeing strong growth.

How will adoption of flow-diverting devices impact the neurovascular embolization coil and coiling-assist device markets?

How has the competitive landscape changed with the emergence of new competitors and products?

The initial results of the HEAT trial demonstrated the superiority of hydrogel-coated embolization coils in comparison to bare platinum coils.

How dramatically will these results impact the use of coated and bare platinum coils? What role will cost play in device uptake?

Which companies will benefit from these favorable results, and which companies will be negatively impacted?